Tabirafusp tedromer

DB19340InvestigationalSmall molecule

Tabirafusp tedromer is under investigation in clinical trial NCT06556368 (A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular...

Formula / weight: C₁₉₄H₃₄₈Br₉N₁₈O₉₃P₉ · 5418.851 g/mol (avg)
Also known as: 1-[1,1,1-tris({3-[2-(2,2,2-tris{[(2-{α-(bromo / ethoxy / hydro / hydroxy)poly[1-(10,10-dimethyl-6-oxido-6-oxo-2,5,7-trioxa-10-aza-6λ5-phosphaundecan-10-ium-1-oyl)-1-methylethane-1,2-diyl]-ω-yl}-2-methylpropanoyl)oxy]methyl}ethoxy)acetamido]propanamido · 3,5,8-Trioxa-4-phosphaundec-10-en-1-aminium,4-hydroxy-N,N,N,10-tetramethyl-9-oxo-, inner salt, 4-oxide, homopolymer,9-arm star compd. with 1,1'-[2-[11,11-bis[15-bromo-11,11-bis[(2-bromo-2-methyl-1-oxopropoxy)methyl]-15-methyl-3,7,14-trioxo-9,13-dioxa-2,6 · Tedromer
Code names: OG-1802

Resolves to

Compound

UNII8ES4CE6CXNCAS2412170-98-8

Structure

InChIKeyGRHIAJGAQUTOSV-UHFFFAOYSA-NSMILES

CC(C)(CC(C)(Br)C(=O)OCCOP([O-])(=O)OCC[N+](C)(C)C)OC(=O)C(COC(=O)C(C)(C)CC(C)(Br)C(=O)OCCOP([O-])(=O)OCC[N+](C)(C)C)(COC(=O)C(C)(C)CC(C)(Br)C(=O)OCCOP([O-])(=O)OCC[N+](C)(C)C)OCC(=O)NCCC(=O)NCC(CNC(=O)CCNC(=O)COCC(COC(=O)C(C)(C)CC(C)(Br)C(=O)OCCOP([O-])(=O)OCC[N+](C)(C)C)(COC(=O)C(C)(C)CC(C)(Br)C(=O)OCCOP([O-])(=O)OCC[N+](C)(C)C)COC(=O)C(C)(C)CC(C)(Br)C(=O)OCCOP([O-])(=O)OCC[N+](C)(C)C)(CNC(=O)CCNC(=O)COCC(COC(=O)C(C)(C)CC(C)(Br)C(=O)OCCOP([O-])(=O)OCC[N+](C)(C)C)(COC(=O)C(C)(C)CC(C)(Br)C(=O)OCCOP([O-])(=O)OCC[N+](C)(C)C)COC(=O)C(C)(C)CC(C)(Br)C(=O)OCCOP([O-])(=O)OCC[N+](C)(C)C)COCCOCCOCCOCCNC(=O)CCOCCOCCOCCOCCNC(=O)CCN1C(=O)C=CC1=O

What you can answer from here — as of August 31, 2026

2Clinical trialsPhase, status and sponsor resolved per trial

Which companies are running trials of Tabirafusp tedromer, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account